These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 17433057

  • 1. Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination.
    Capablo JL, Franco R, de Cabezón AS, Alfonso P, Pocovi M, Giraldo P.
    Epilepsia; 2007 Jul; 48(7):1406-8. PubMed ID: 17433057
    [Abstract] [Full Text] [Related]

  • 2. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
    Canda E, Kose M, Kagnici M, Ucar SK, Sozmen EY, Coker M.
    Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116
    [No Abstract] [Full Text] [Related]

  • 3. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
    Serratrice C, Swiader L, Serratrice J.
    J Med Case Rep; 2015 Jun 23; 9():146. PubMed ID: 26100396
    [Abstract] [Full Text] [Related]

  • 4. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease.
    Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P.
    Am J Hematol; 2005 Nov 23; 80(3):223-9. PubMed ID: 16247743
    [Abstract] [Full Text] [Related]

  • 5. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G, Lombardo R, Di Francesco E, Parrinello L, Di Raimondo F, Fiumara A.
    J Med Case Rep; 2016 Nov 08; 10(1):315. PubMed ID: 27821156
    [Abstract] [Full Text] [Related]

  • 6. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
    Amato D, Patterson MA.
    J Med Case Rep; 2018 Jan 27; 12(1):19. PubMed ID: 29373994
    [Abstract] [Full Text] [Related]

  • 7. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM, Barnett NL, Kolodny EH.
    Clin Ther; 2005 Aug 27; 27(8):1215-27. PubMed ID: 16199246
    [Abstract] [Full Text] [Related]

  • 8. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
    Ceravolo F, Grisolia M, Sestito S, Falvo F, Moricca MT, Concolino D.
    J Med Case Rep; 2017 Jan 20; 11(1):19. PubMed ID: 28103924
    [Abstract] [Full Text] [Related]

  • 9. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat.
    Mikosch P, Reed M, Baker R, Holloway B, Berger L, Mehta AB, Hughes DA.
    Calcif Tissue Int; 2008 Jul 20; 83(1):43-54. PubMed ID: 18553043
    [Abstract] [Full Text] [Related]

  • 10. Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy.
    Prescrire Int; 2005 Oct 20; 14(79):168-70. PubMed ID: 16285070
    [Abstract] [Full Text] [Related]

  • 11. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
    Elstein D, Dweck A, Attias D, Hadas-Halpern I, Zevin S, Altarescu G, Aerts JF, van Weely S, Zimran A.
    Blood; 2007 Oct 01; 110(7):2296-301. PubMed ID: 17609429
    [Abstract] [Full Text] [Related]

  • 12. Gaucher disease due to saposin C deficiency, previously described as non-neuronopathic form--no positive effects after 2-years of miglustat therapy.
    Tylki-Szymańska A, Groener JE, Kamiński ML, Ługowska A, Jurkiewicz E, Czartoryska B.
    Mol Genet Metab; 2011 Dec 01; 104(4):627-30. PubMed ID: 21978771
    [Abstract] [Full Text] [Related]

  • 13. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN.
    J Bone Miner Res; 2007 Jan 01; 22(1):119-26. PubMed ID: 17032149
    [Abstract] [Full Text] [Related]

  • 14. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.
    Moyses C.
    Philos Trans R Soc Lond B Biol Sci; 2003 May 29; 358(1433):955-60. PubMed ID: 12803929
    [Abstract] [Full Text] [Related]

  • 15. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
    Pastores GM, Elstein D, Hrebícek M, Zimran A.
    Clin Ther; 2007 Aug 29; 29(8):1645-54. PubMed ID: 17919546
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease.
    Pastores GM.
    BioDrugs; 2010 Feb 01; 24(1):41-7. PubMed ID: 20055531
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Treatment of bone involvement in Gaucher diseases with imiglucerase combined with miglustat].
    Marie I.
    Presse Med; 2009 Dec 01; 38 Suppl 2():2S68-70. PubMed ID: 20304314
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.